OBJECTIVES The objectives of this study were to determine if hypertensive patients with comorbid diabetes mellitus (DM) and/or chronic kidney disease (CKD) receiving a pharmacist intervention had a greater reduction in mean blood pressure (BP) and improved BP control at 9 months compared with those receiving usual care; and compare Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7) guideline and 2014 guideline (JNC 8) BP control rates in patients with DM and/or CKD. METHODS This cluster randomized trial included 32 medical offices in 15 states. Clinical pharmacists made treatment recommendations to physicians at intervention sites. This post hoc analysis evaluated mean BP and BP control rates in the intervention and control groups. MAIN RESULTS The study included 335 patients (227 intervention, 108 control) when mean BP and control rates were evaluated by JNC 7 inclusion and control criteria. When JNC 8 inclusion and control criteria were applied, 241 patients (165 intervention, 76 control) remained and were included in the analysis. The pharmacist-intervention group had significantly greater mean systolic blood pressure reduction compared with usual care at 9 months (8.64 mm Hg; 95% confidence interval [CI] À12.8 to À4.49, p<0.001). The pharmacist-intervention group had significantly higher BP control at 9 months than usual care by either the JNC 7 or JNC 8 inclusion and control groups (adjusted odds ratio [OR] 1.97, 95% CI 1. p=0.0470 and OR 2.16, p=0.0102, respectively). PRINCIPAL CONCLUSIONS This study demonstrated that a physician-pharmacist collaborative intervention was effective in reducing mean systolic BP and improving BP control in patients with uncontrolled hypertension with DM and/or CKD, regardless of which BP guidelines were used.
Hypertension (HTN) affects approximately one of every three adults in the United States and contributed to more than 400,000 deaths in 2014. 1 In addition, HTN increases the risk for cardiovascular disease, including myocardial infarction (MI) and stroke.
2 Independently, diabetes mellitus (DM) and chronic kidney disease (CKD) are responsible for a high degree of cardiovascular complications. [3] [4] [5] [6] Hypertension with DM or CKD multiplies the risk for cardiovascular-related death, MI, angina pectoris, and stroke. 7, 8 Self-reported data found that 11.9% of individuals in the United States have either physician-diagnosed or undiagnosed DM. 9 Among patients with both HTN and DM, only 29.6% meet their blood pressure (BP) goal. 10 Blood pressure control reduces cardiovascular complications in patients with both HTN and DM. 11, 12 For each 10 mm Hg decrease in mean systolic blood pressure (SBP), there is an associated 12% reduction in diabetic complications, 15% reduction in deaths related to DM, 11% reduction in MI, and 13% reduction in microvascular complications. 13 National Health and Nutrition Examination Survey data found that the prevalence of CKD in those with undiagnosed and diagnosed HTN was 22.0% and 27.5%, respectively.
14 Populationbased data suggest that awareness, control, and adequate treatment of other cardiovascular complications are suboptimal in those with CKD. Studies have shown that even small elevations of BP place patients at increased risk for progression to end-stage renal disease. 15, 16 Team-based care including pharmacists and nurses is a proven method to improve BP control. [17] [18] [19] [20] The physician-pharmacist collaborative management (PPCM) model involves close collaboration within primary care settings to optimize drug therapy and promote preventive health measures. 21 Studies have shown that addition of pharmacists to the health care team improves BP in those with DM. [22] [23] [24] Although randomized controlled trials have examined pharmacist contributions to BP outcomes in those with DM, many studies were conducted in community pharmacies, outside the United States, or with limited numbers of medical offices. 25, 26 The Collaboration Among Pharmacists and Physicians to Improve Blood Pressure Now (CAPTION) study was a cluster randomized implementation trial measuring the impact of PPCM on patients with uncontrolled HTN in 32 medical offices across the United States. 27 The primary end point in CAPTION did not achieve statistical significance; BP control was 43% in the intervention group and 34% in the control group at 9 months (adjusted odds ratio [OR] 1.57, 95% confidence interval [CI] 0.99-2.50, p=0.059). 27 The CAPTION trial defined BP control for those with DM and CKD as less than 130/80 mm Hg based on the then current Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7) guidelines. 28 In addition, the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial, published during the CAPTION trial, did not find evidence to support a goal SBP below 140 mm Hg in patients with DM. 29 Some clinicians in the CAPTION trial anecdotally expressed discomfort with the JNC 7 goals.
The CAPTION investigators conducted a sensitivity analysis using the definitions from the newer 2014 evidence-based guidelines for the management of high BP in adults (JNC 8) that recommended higher BP goals (140/90 mm Hg) for patients older than 60 years and for patients with DM or CKD. 30 When the higher goals were used, BP control was achieved in 61% of intervention patients and 45% of controls at 9 months (adjusted OR 2.03, 95% CI 1.29-3.22, p=0.003). More than half of the patients enrolled in CAPTION had either DM or CKD. 27 Therefore, it was theorized that the lower BP control rates might be explained by providers who lowered BP to a point close to the JNC 7 BP goal in those with DM or CKD but may not have quite reached the aggressive less than 130/ 80 mm Hg threshold.
The aims of the present CAPTION substudy are to determine if hypertensive patients with comorbid DM and/or CKD receiving a pharmacist intervention had improved BP control and greater reduction in mean BP at 9 months compared with those receiving usual care and to compare JNC 7 and JNC 8 BP control rates in CAPTION patients with DM and/or CKD.
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Materials and Methods
The main study design, baseline data, and results were published previously. 27, 31 The CAP-TION study included 32 medical offices from 15 U.S. states and was a prospective cluster randomized multicenter clinical trial. Offices were stratified based on the level of pharmacy services provided and percentage of minority patients. 31, 32 Offices were then randomized to one of the three study arms: usual BP care, a 9-month BP intervention, or a sustained 24-month intervention. The two intervention arms were designed to be the same for the first 9 months so they could be combined and compared with usual care. The analyses for the present substudy were planned post hoc and included mean BP reduction and BP control during the first 9 months of the intervention for patients with comorbid DM and/or CKD.
Patient Recruitment
The institutional review board in each medical office approved this study. Patients were included if they were English-or Spanish-speaking men or women older than 18 years with diagnosed HTN; had uncontrolled HTN defined as a SBP 140 mm Hg or greater or diastolic blood pressure (DBP) 90 mm Hg or greater for uncomplicated HTN and a SBP of 130 mm Hg or greater or DBP 80 mm Hg or greater for patients with DM or CKD; and received care from one of the participating medical clinics. A patient was classified with DM/CKD if he or she had been diagnosed with either condition at baseline, as reported on the "Diagnosed Conditions" electronic case report form. If neither condition was reported, a further examination of CKD was based on the calculated glomerular filtration rates (GFRs) from the patient's two most recent creatinine tests at baseline. Glomerular filtration rate was calculated using the modification of diet in renal disease study equation. 33 In the present substudy, only patients with diagnosed DM, CKD, or both DM and CKD were included in the analysis. Patients could have either type 1 or type 2 DM. The study did not determine which type of DM these patients had, but the vast majority had type 2 DM.
Patients were excluded if they had current signs of a hypertensive emergency (acute angina, stroke, or renal failure); severe HTN (SBP higher than 200 or DBP higher than 114 mm Hg); history of MI, stroke, or unstable angina in the prior 6 months; systolic dysfunction with left ventricular ejection fraction less than 35% determined by echocardiography, nuclear medication imaging, or ventriculography; renal insufficiency as defined by a GFR less than 20 ml/minute or documented proteinuria greater than 1 g/day; significant hepatic disease including cirrhosis, hepatitis B or C, or lab abnormalities (serum alanine transaminase or aspartate aminotransferase more than twice the upper limit of normal or total bilirubin higher than 1.5 mg/dl) in the prior 6 months; pregnancy; diagnosis of pulmonary HTN or sleep apnea; life expectancy estimated at less than 2 years; residence in a nursing home or a diagnosis of dementia, and inability to give informed consent or impaired cognitive function (defined as 3 or more errors on the 10-item Pfeiffer). 34 A study coordinator (generally a medical assistant or nurse) employed within each office recruited subjects and collected data. The study coordinator used billing records to identify patients with HTN. Patient lists were then submitted to the biostatistician who randomized the list. The study coordinator then selected patients in order from the randomized list to avoid selection bias. All patients who agreed to participate signed written informed consent.
Data Collection
Study coordinators at all offices collected data at baseline and at 9 and 24 months. 31 Study coordinators were trained in Iowa City in these areas: ethical treatment of human subjects, informed consent documents, protocol methods, and BP measurement using the automated Omron HEM 907-XL device (Omron Healthcare; Bannockburn, IL). 35 Blood pressure was measured three times in the sitting position using the appropriate technique. The first BP reading was not used. The second and third BP measurements were averaged, but if the SBP or DBP values varied by more than 4 mm Hg, a fourth measurement was taken, and the two closest readings between the second, third, and fourth measurements were averaged. Study coordinators then collected information regarding demographics and past medical history, including DM and CKD, from both the patient report and the medical record.
All data were uploaded into an encrypted web-based data management system designed and managed by the Data Coordinating Center (DCC). The DCC conducted a centralized 
Pharmacist Intervention
Pharmacists at each medical office in the intervention arm completed a patient interview including medication history of all prescription, nonprescription, and herbal medications; assessment of health literacy including patient knowledge of BP medications, indication of each medication, goals of therapy, medication dosages and frequency, and potential side effects; contraindications to each medication; and issues related to adherence and monitoring.
Pharmacists were encouraged first to assess medication knowledge and then educate the patient on HTN and the importance of following the pharmacotherapy plan properly. Pharmacists also provided recommendations on lifestyle modification, a wallet card listing all current medications and doses, and pharmacist contact information. In certain patients warranting additional adherence aid, pharmacists encouraged the use of medication logs or medication boxes. The pharmacist then created an individualized care plan with BP goal and medication recommendations. Care plans were presented to the physician either verbally or, if preferred by the physician, by electronic communication. If the physician decided to make modifications, the pharmacist finalized the plan. The proposed intervention included scheduled face-to-face visits with the patient at baseline, 1, 2, 4, 6, and 8 months, and a telephone call at 2 weeks. Additional telephone calls were added as needed for those with uncontrolled HTN. Although a protocol was suggested to implement the intervention, the study was designed as a more pragmatic effectiveness trial. Thus clinical pharmacists were free to modify the intervention based on their professional judgment, including the frequency of visits with patients. No treatment protocols were used, and clinical pharmacists were only instructed to follow the JNC 7 guidelines. Investigators tracked the number of visits with the pharmacists to determine how closely pharmacists adhered to the proposed intervention frequency.
Analysis
The analysis for the present study compared mean SBP and DBP for patients with DM and/ or CKD receiving a pharmacist intervention with those receiving usual care. An additional analysis was performed comparing BP control in patients with DM and/or CKD receiving the pharmacist intervention with those receiving usual care with JNC 8 inclusion and control criteria. The CAPTION trial enrolled patients with uncontrolled HTN, giving consideration to diagnoses of DM or CKD based on the JNC 7 criteria. If patients had a diagnosis of HTN and DM and/or CKD, their BP goal was 130/ 80 mm Hg. To evaluate the effect of the intervention using JNC 8 criteria, 94 of the initial 335 subjects from the trial were excluded based on the higher BP goals (lower than 140/ 90 mm Hg). For this reason, fewer original patients met the criteria for uncontrolled BP using the JNC 8 criteria. The analyses were secondary, post hoc, and comparable with the main CAPTION analyses. 27, 31 Mean SBP and DBP were analyzed using a linear mixed model with random effects for office and patient within office. The center random effects were assumed to be normally distributed and have a compound symmetric covariance structure, and the nested within-subjects errors were assumed to have an AR(1) covariance structure. Blood pressure control was analyzed using a nonlinear mixed effects model with the logit link function. Like the linear models, the office random effects were assumed to be normally distributed with a compound symmetric covariance structure, and the nested within-subjects errors were assumed to have an AR(1) covariance structure. Potential confounding variables at baseline were examined, and sensitivity analyses were performed to adjust for any covariates that differed across treatment groups. 27 Blood pressure was assumed to be uncontrolled if a BP value was missing at 9 months. This approach has been used in many trials and is a conservative method to recognize that if a patient missed the visit, BP was more likely to be uncontrolled than controlled. 18, 36 No multiple imputation was used to account for missing BPs in the linear models. These same analyses were used for both the JNC 7 and JNC 8 analysis groups for mean BPs. The only difference was that patients in the original cohort with baseline BPs below the new threshold (lower than 140/90 mm Hg) were not included in the JNC 8 cohort because those with controlled BP would not have met the original inclusion criteria for the study.
Results
Of the 335 patients included in this study, 242 had DM, 43 had CKD, and 50 had both. Patient recruitment began in March 2010, and the last patient completed the trial in June 2013 (Figure 1) . Therefore, the JNC 7 guidelines were in place throughout the entire study. No differences were found in the intervention effect related to sex. Table 1 displays the baseline demographic information for the patients included in the present study. Table 2 shows mean BP at baseline and 9 months between patients receiving the pharmacist intervention and usual care. The pharmacistintervention group achieved a model-adjusted SBP and DBP reduction of 8.64 mm Hg (95% CI À12.8 to À4.49, p<0.001) and 2.90 (95% CI À5.55 to À0.25, p=0.0323) greater than that of the control group, respectively. Table 3 shows BP control rates at 9 months between patients receiving the pharmacist intervention and those receiving usual care for both JNC 7 and JNC 8 BP goals. The pharmacist intervention, regardless of BP goal, was able to reach significant BP control compared with usual care in both the JNC 7 analysis (adjusted OR 1.97, 95% CI 1.01-3.86, p=0.0470) and the JNC 8 analysis (adjusted OR 2.16, 95% CI 1.21-3.85, p=0.0102).
The numbers and types of pharmacist recommendations and the medications used in the CAPTION trial were previously published. 37 No differences were found in medication classes 13,839 used between intervention and control groups following the intervention with the exception that diuretics and aldosterone antagonists were used more frequently in the intervention group.
Discussion
This study demonstrated that a pharmacist intervention significantly reduced mean SBP in patients with uncontrolled HTN and DM and/or CKD compared with usual care. Most importantly, the pharmacist-intervention group had significantly higher BP control at 9 months compared with usual care, regardless of which BP goal was used. The level of significance was higher in the JNC 8 analysis compared with that of the JNC 7 analysis. Findings based on race, income, education, and insurance status were previously published. 38 The pharmacist intervention had similar effects in these subgroups as with the entire study population, including those previously taking three or more antihypertensive medications at baseline. 39 As anticipated, a considerable difference in control rates was found between pharmacist intervention and usual care when JNC 7 and JNC 8 BP goals were applied because JNC 8 relaxed goals for DM and CKD. We theorize that the pharmacist intervention was successful in getting most patients close to their 130/80 mm Hg threshold. However, because the ACCORD trial and other commentaries published during our study questioned these lower goals, some clinicians may have not felt comfortable lowering BP to these levels. 29 BMI = body mass index; BP = blood pressure; CKD = chronic kidney disease; COPD = chronic obstructive pulmonary disease; DBP = diastolic blood pressure; DJD = degenerative joint disease; min = minimum; max = maximum; SBP = systolic blood pressure; SD = standard deviation; TIA = transient ischemic attack.
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In previous studies, PPCM was shown both to reduce mean BP and increase BP control. 17 In the original CAPTION trial, the difference in mean BP between the pharmacist intervention and usual care for all study patients was À6.1/ À2.9 mm Hg (p<0.001 and p=0.003, respectively) at 9 months. 27 However, the primary outcome was BP control that did not quite achieve statistical significance (p=0.059), in part due to greater interclinic variability than originally expected. 27 Newer studies and the most recent HTN 2017 guidelines supported by multiple professional organizations recommend a BP of less than 130/80 mm Hg in almost all individuals with HTN. 40, 41 These new goals will be difficult to achieve, especially in patients with comorbidities and socioeconomic disadvantages.
Other investigators have examined the impact of team-based care in the treatment of multiple chronic conditions. The Fremantle Diabetes Study demonstrated positive BP control outcomes (p=0.043), but it should be noted that the investigators defined BP control as lower than 135/85 mm Hg. 42 A group of investigators showed improved mean BP with a pharmacist intervention in North Carolina internal medicine offices. 24 The pharmacist-intervention group in this study had a mean BP reduction of 7 mm Hg over the course of 12 months, whereas the control group had a mean BP increase of 2 mm Hg, making the difference 9 mm Hg between groups. In contrast, the patient group receiving pharmacist intervention in the present study had a mean BP reduction of~16 mm Hg, with the usual-care group achieving an 8 mm Hg reduction. A randomized study conducted in a community health center found a significant difference in mean BP after a 9-month pharmacist intervention, but baseline SBP for both intervention and control was already quite low (130.0 and 130.7 mm Hg, respectively). 25 A study conducted with patients from 14 community pharmacies in Edmonton, Alberta, Canada, found that care from pharmacist-nurse teams significantly improved BP control and reduced mean BP in those with HTN and DM. 26 By comparison, the patient population in the Canadian study had lower mean BP at baseline and considerably less BP reduction (5.6 mm Hg) than the present study. Several studies have found that the addition of a pharmacist to a primary care team was effective in reducing mean BP and meeting BP targets. 22, 23 Although patients in one of the studies achieved significantly improved BP control (p=0.02), the difference in mean BP between intervention and control groups was modest (4.9 mm Hg). 22 The present study is unique because it was a cluster randomized controlled trial in patients enrolled from 32 medical offices across 15 U.S. states. One strength of the CAPTION trial was that it was designed as a more pragmatic effectiveness trial. A standard practice, protocol, medications, or method of communication with physicians was not required. Some pharmacists used collaborative practice agreements to initiate and adjust therapy, whereas others had all medication changes approved by the physician. The only goal established for the pharmacist was to achieve BP control using JNC 7 criteria. Overall, 54% of patients were from underrepresented minority groups, with 71% African American, 26% Hispanic, and 3% other. 27 In addition, 49% had an income less than $25,000/year, and 25% used Medicaid, self-pay, or no insurance for their health care payment. 38 Finally, 27% of patients met the definition of treatment-resistant HTN. 39 The intervention was as effective, or nearly as effective, for all these groups despite the challenges of achieving BP control in these patient groups. In this regard, the findings are generalizable to a broad range of practices and patient populations.
The most likely reason for improved BP in the intervention group was intensification of suboptimal regimens. Significantly more medication changes (4.9 AE 5.1 vs 1.1 AE 1.6, p=0.0003) and medications added or doses increased (3.2 AE 3.2 vs 0.7 AE 1.1, p=0.0002) occurred in the intervention group compared with the control group, respectively. 37 The intervention group was treated with significantly more diuretics and aldosterone antagonists, the latter likely used for patients with treatment-resistant HTN.
The disadvantage of efficacy trials without compulsory treatment and care protocols is that the intervention may not be completely implemented, and significant variability may occur across sites. For instance, BP control rates ranged from 20-71% in the 20 intervention offices, and there was no clear indication that higher numbers of patients from minority groups, with lower income, no insurance, less education, or with diabetes or CKD, explained these variable results. 43 These findings suggest but cannot prove that variability in pharmacist practice styles may have contributed to the differences in BP control across sites. 44 This study had important limitations. Fifteen percent of patients did not complete the 9-month visit, but this rate of missing data was actually lower than expected. A conservative approach was used to analyze missing data, which is a strength of the study. In addition, this was a post hoc analysis. However, the general findings in these patients with DM and/or CKD were similar to the overall study population that were prospectively enrolled. Despite these limitations, the addition of a pharmacist to the care team improved BP outcomes in groups at high cardiovascular risk who often have poor BP control. 45 
Conclusion
This study demonstrated that an intervention utilizing pharmacists embedded within medical offices who were members of the care team reduced mean SBP in those with uncontrolled HTN and comorbid DM and/or CKD. In addition, regardless of which guideline criteria were used to specify BP control, the pharmacist intervention improved patient BP control. Additional studies are warranted to support the effectiveness of PPCM in patients with HTN, especially in light of the new HTN guidelines that again suggest lower BP goals in patients with DM and CKD similar to the JNC 7 guidelines. Our findings suggest that a team-based care model including pharmacists can be implemented to improve BP control and reduce mean BP in patients with uncontrolled HTN and DM and/or CKD.
